QuidelOrtho shed 5.6% on Tuesday to close at $17.00, pulling back from the rally highs even as Citigroup raised its price target the same morning — a split signal that captures the stock's awkward positioning ahead of a July 29 earnings print.
The most notable development this week came from the Street. Citigroup's Patrick Donnelly raised his target from $13 to $18 this morning while keeping a Neutral rating — the clearest sign yet that analysts are acknowledging the stock's recovery, even if they won't back it with conviction. JP Morgan lifted its own target to $12 last week but held its Underweight. The mean target across the coverage universe now sits at $20.13, which is above the current price for the first time in months. That said, the recent trajectory of cuts — Jefferies slashing from $35 to $12.50 in early May, Citigroup cutting from $30 to $13 around the same time — makes the consensus feel fragile rather than supportive. The stock has rallied past most of those reset targets, but the Street has yet to follow with upgraded conviction. The July 29 print will be the first real test of whether that reset was enough.
Short interest remains the structural overhang. Bears hold 18.4% of the free float — down fractionally on the week but up 4.5% over the past month, meaning the rally has not triggered any meaningful covering. The ORTEX short score holds near 67.5, a level that has been remarkably stable over the past two weeks. Borrowing costs tell the other side of that story: at 0.53%, cost to borrow is near its lowest in six months, down 7% on the week. Availability is running at 217% of existing short interest, meaning there are more than two shares available to borrow for every one already borrowed — a loose lending market that places no natural squeeze pressure on the bears. They are not trapped; the cost of staying short is minimal.
Options positioning has shifted notably. The put/call ratio stands at 1.42, well below the 20-day average of 1.61 and far below the spike to 2.4 seen in late June. That late-June peak coincided with peak defensiveness; the recent drop suggests options traders have rotated away from extreme downside protection — though a PCR of 1.42 still indicates more puts than calls, and the reading remains elevated relative to the full 52-week range of 0.21 to 2.41. The direction of travel is toward less panic, not toward outright optimism.
On valuation, the numbers are stark. The stock trades at 5.5x trailing earnings and 0.47x book — both metrics that reflect how cheaply the market values a business still working through the post-pandemic diagnostics reset. Enterprise value sits at roughly $3.7 billion against an EV/EBITDA multiple near 5.5x. The EPS momentum rank is in the 75th percentile on a 30-day basis but drops to the 19th percentile over 90 days — a reminder that the recent improvement is fresh and not yet a durable trend. Among correlated peers, ABT and BAX both gained on the week, up 3.4% and 3.8% respectively, while OBIO fell 16.6% — QDEL's 3% weekly decline sits in the middle of the peer range, consistent with stock-specific pressure rather than a sector-wide selloff.
The focus now narrows to what July 29 delivers: whether the rally was prescient or premature, and whether short sellers — who have held their ground through an 18-point recovery — finally find a reason to move.
See the live data behind this article on ORTEX.
Open QDEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
